Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: Comparison with other angiotensin II type 1 receptor blockers

International Journal of Clinical Pharmacology Research

Volumn 25, Issue 1, 2005, Pages 41-46

  Kakuta, Hirotoshi ^a   Sudoh, K ^a   Sasamata, M ^a   Yamagishi, S ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG RECEPTOR BINDING; HEART PROTECTION; HUMAN; HYPERTENSION; PATHOGENESIS; RECEPTOR AFFINITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BINDING, COMPETITIVE; CELL MEMBRANE; HUMANS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 17644399461     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Higaki J., Baba S., Katsuya T., et al. Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men. The Suita study. Circulation, 101, 2060, 2000.
2. Burnier M., Brunner H.R. Angiotensin II receptor antagonists. Lancet, 355, 637, 2000.
3. De Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International Union of Pharmacology, XXIII. The angiotensin II receptors. Pharmacol. Rev., 52, 415, 2000.
4. 2 receptor: New insights into an old system. Regul. Pept., 99, 175, 2001.
5. Siragy H.M. Angiotensin receptor blockers: How important is selectivity? Am. J. Hypertens., 15, 1006, 2002.
6. Pylypchuk G. B. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann. Pharmacother., 32, 1060, 1998.
7. RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med., 345, 861, 2001.
8. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet, 359, 995, 2002.
9. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet, 362, 772, 2003.
10. Sudoh K., Funatsu T., Kakuta H., Uemura T., Miyata K. Binding properties of Telmisartan (Micardis®) for human angiotensin II receptors. Clin. Pharmacol. Ther., 13, 111, 2003.
11. Burnier M., Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press., 10(Suppl 1), 6, 2001.
12. Muller J.E., Tofler G.H., Stone P.H. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation, 79, 733, 1989.
13. Marler J.R., Price T.R., Clark G.L., et al. Morning increase in onset of ischemic stroke. Stroke, 20, 473, 1989.
14. Muller J.E., Ludmer P.L., Willich S.N., et al. Circadian variation in the frequency of sudden cardiac death. Circulation, 75, 131, 1987.
15. Kawasaki T., Cugini P., Uezono K., et al. Circadian variations of total renin, plasma renin activity and plasma aldosterone in clinically healthy young subjects. Hor. Metab. Res., 22, 636, 1990.
16. Imai Y., Hozawa A., Ohkubo T., et al. Predictive values of automated blood pressure measurement: what can we learn from the Japanese population-the Ohasama study. Blood Press. Monit., 6, 335, 2001.
17. Joint National Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure (JNC 6). Arch. Intern. Med., 157, 2413, 1997.
18. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J. Hypertens., 17, 151, 1999.
19. Mallion J.M., Siche J.P., Lacourcière Y. and Telmisartan Blood Pressure Monitoring Group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J. Hum. Hypertens., 13, 657, 1999.
20. Lacourcière Y., Krzesinski J.M., White W.B., Davidai G., Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press. Monit., 9, 203, 2004.
21. Lacourcière Y., Lenis J., Orchard R., et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press. Monit., 3, 295, 1998.
22. Gardner S.F., Franks A.M. Olmesartan medoxomil: The seventh angiotensin receptor antagonist. Ann. Pharmacother., 37, 99, 2003.
23. 1-receptor blockers. Blood Press., 10(Suppl. 3), 33, 2001.
24. Unger T. Significance of angiotensin type 1 receptor blockade: Why are angiotensin II receptor blockers different? Am. J. Cardiol., 84, 9S, 1999.
25. Delacrétaz E., Nussberger J., Biollaz J., Waeber B., Brunner H.R. Characterization of the Angiotensin II Receptor Antagonist TCV-116 in healthy volunteers. Hypertension, 25, 14, 1995.